Ascendia Pharmaceuticals, Inc. – Trademark Portfolio

Entity Type: 03

Ascendia Pharmaceuticals, Inc. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 9 filings in this category. Currently, 3 trademarks are registered. Notable registered marks include LIPIDSOL, MAKING THE INSOLUBLE SOLUBLE, and ASCENDIA PHARMACEUTICAL SOLUTIONS. The owner is based in North Brunswick, NJ.

661 US Highway One, Unit B

North Brunswick, NJ 08902

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

Ascendia Pharmaceuticals, Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (9 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Ascendia Pharmaceuticals, Inc. have?

Ascendia Pharmaceuticals, Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 abandoned, 4 cancelled.

What trademark classes does Ascendia Pharmaceuticals, Inc. file in?

Ascendia Pharmaceuticals, Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 42 (Computer & Scientific). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Ascendia Pharmaceuticals, Inc.'s most well-known trademarks?

Ascendia Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as LIPIDSOL, MAKING THE INSOLUBLE SOLUBLE, and ASCENDIA PHARMACEUTICAL SOLUTIONS. These are among 3 currently registered trademarks in the portfolio.

What is Ascendia Pharmaceuticals, Inc.'s trademark registration success rate?

Ascendia Pharmaceuticals, Inc. has a 33% trademark registration rate, with 3 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.